Newron Pharmaceuticals - Positive interim trial results in schizophrenia
Newron Pharmaceuticals’ share price has responded well to its announcement of encouraging interim efficacy data for the use of evenamide as an...
710 Views
Newron Pharmaceuticals - Evenamide catalyst approaching
Newron Pharmaceuticals is focused on the development of novel compounds for the treatment of various neurological conditions. Heading the R&D...
756 Views
Newron Pharmaceuticals - Evanamide potential expanding in schizophrenia
Newron Phamaceuticals has announced encouraging interim safety and efficacy data for the use of evanamide, a glutamate modulator, as an add-on...
765 Views
Newron Pharmaceuticals - Pivotal progress on schizophrenia therapy
Newron, a Switzerland-quoted Italian company, is developing evenamide (30mg twice per day) to meet the major unmet need for new therapies to help...
406 Views
Newron Pharmaceuticals - Evenamide validation underway
Newron is developing evenamide (30mg twice per day) as an add-on to treat poorly managed and refractory schizophrenia. A potentially pivotal Phase...
1.3k Views